Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 205,28 € (-7,53 %). La mediana es de 218,43 € (-1,61 %).
| Comprar |
18 |
| Mantener |
6 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Glaukos outlines growth with Epioxa and iDose, but sees reimbursement risks
At the Wells Fargo conference, Glaukos presented its growth strategy centered on Epioxa (corneal health) and iDose (interventional glaucoma) and reported initial Epioxa revenues ($11m in the first full quarter, ~180 treated eyes) as well as sequential iDose growth of about $20m. Management expects a positive contribution to EPS from Q4 2024 and, given high gross margins, sees a path to operating margins of 30–40% with scale. Key uncertainties include delays in application reviews, possible changes to Medicare reimbursement (LCD) and market access; management is cautious for H2 2024 in the near term. Glaukos plans to continue advancing product launches, including a portable keratoconus screening device by the end of 2024, and expects further study data and approvals through 2027. » Más en de.investing.com
Glaukos hits new all-time high of $190.27 after strong Q2 results
Glaukos shares rose to a record high of $190.27; market capitalization stands at $11.03 billion. In Q2 2026 the company reported revenue of $185.6 million (+49.5% YoY), beating analysts' estimates, after which the full-year revenue guidance was raised. Following the results, several firms raised their price targets, while InvestingPro currently rates the stock as overvalued and 11 analysts revised their earnings estimates upward. The price increase follows a year-to-date gain of 111.6% and underscores positive investor sentiment toward Glaukos' growth prospects in the medtech sector. » Más en de.investing.com
Glaukos hits record high of $184.45 after strong Q2 results
Glaukos's stock rose to a record high of $184.45, bringing market capitalization to $10.83 billion. In the second quarter of 2026 the medical device company generated $185.6 million in revenue (+50% year‑on‑year) and reported a loss per share that was smaller than expected, after which Glaukos raised its full‑year revenue guidance. Several analysts lifted their price targets, while an InvestingPro analysis classifies the stock at current levels as possibly overvalued. » Más en de.investing.com
Glaukos raises full-year forecast after strong Q2 with 49.54% revenue growth
Glaukos reported a 49.54% revenue increase to $185.61 million in the second quarter, significantly beating analysts’ expectations. Management has sharply raised the full-year forecast, prompting heavy accumulation of the stock on high trading volume. The commercial breakthrough of the glaucoma implant iDose TR is viewed as a driver of long-term dynamic growth. » Más en finanzen.net
Glaukos reaches 52-week high at $161.67
Glaukos shares climbed to a new 52-week high of $161.67; the stock is currently trading at $163.01, about 1% above that high. Over the past year the stock rose 70.14%, year-to-date it is up 34%, and it gained 27% in the last six months. InvestingPro currently rates the stock as significantly overvalued. Glaukos also reported completion of patient recruitment for the phase-2 study of GLK-321; analysts including Stifel, Piper Sandler and William Blair reiterate positive views and see potential for products such as iDose and Epioxa. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 186,31 M | 63,73 % |
| Beneficio bruto | 158,79 M | 77,97 % |
| Beneficio neto | 1,78 M | 112,88 % |
| EBITDA | 10,91 M | 376,36 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 13,11 mil M € |
Número de acciones | 59,2 M |
Máximo/mínimo de 52 semanas | 232,26 € - 79,47 € |
| Dividendos | No |
Beta | 0,69 |
Ratio P/E | -82,74 |
Ratio PEG | 0,73 |
Ratio P/B | 20,04 |
Ratio P/S | 20,86 |
Perfil de la empresa
Glaukos Corporation, una empresa de tecnología médica oftalmológica y farmacéutica, se centra en el desarrollo de terapias novedosas para el tratamiento del glaucoma, los trastornos corneales y las enfermedades de la retina. Ofrece iStent, iStent inject e iStent inject W, stents de micro-derivación que mejoran el flujo de salida del humor acuoso, que se insertan durante la cirugía de cataratas para tratar el glaucoma de ángulo abierto de leve a moderado. La cartera de productos en desarrollo de la compañía incluye iStent Infinite, un producto de tres stents diseñado para su uso como procedimiento independiente en pacientes con glaucoma refractario; e iDose TR, un implante inyectable dirigido basado en su plataforma de dispositivos a microescala, diseñado para administrar niveles terapéuticos de medicación. La empresa comercializa sus productos a través de una organización de ventas directas, así como mediante distribuidores en Estados Unidos y en el extranjero. Glaukos Corporation se constituyó en 1998 y tiene su sede en San Clemente, California.
| Nombre | Glaukos |
| CEO | Thomas William Burns |
| Sede | Aliso Viejo,
ca Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Bienes duraderos del hogar |
| Salida a bolsa | 03/12/2009 |
| Empleados | 1094 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | GKOS |
Frankfurt | 6GJ.F |
Düsseldorf | 6GJ.DU |
München | 6GJ.MU |